Jaypirca (pirtobrutinib tablets) — Cigna
Small Lymphocytic Lymphoma (SLL)
Initial criteria
- Patient age ≥ 18 years AND
- Patient has resistance or intolerance to Imbruvica (ibrutinib), Calquence (acalabrutinib), or Brukinsa (zanubrutinib) OR
- Patient has relapsed or refractory disease AND has tried a Bruton tyrosine kinase (BTK) inhibitor AND has tried at least one B-cell lymphoma-2 (BCL-2) inhibitor (e.g., Venclexta [venetoclax])
Approval duration
1 year